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Abstract
Inflammasomes are multi-protein complexes that control the production of pro-inflammatory cytokines such as IL-1b.
Inflammasomes play an important role in the control of immunity to tumors and infections, and also in autoimmune
diseases, but the mechanisms controlling the activation of human inflammasomes are largely unknown. We found that
human activated CD4+CD45RO+ memory T-cells specifically suppress P2X7R-mediated NLRP3 inflammasome activation,
without affecting P2X7R-independent NLRP3 or NLRP1 inflammasome activation. The concomitant increase in pro-IL-1b
production induced by activated memory T-cells concealed this effect. Priming with IFNb decreased pro-IL-1b production in
addition to NLRP3 inflammasome inhibition and thus unmasked the inhibitory effect on NLRP3 inflammasome activation.
IFNb suppresses NLRP3 inflammasome activation through an indirect mechanism involving decreased P2X7R signaling. The
inhibition of pro-IL-1b production and suppression of NLRP3 inflammasome activation by IFNb-primed human
CD4+CD45RO+ memory T-cells is partly mediated by soluble FasL and is associated with down-regulated P2X7R mRNA
expression and reduced response to ATP in monocytes. CD4+CD45RO+ memory T-cells from multiple sclerosis (MS) patients
showed a reduced ability to suppress NLRP3 inflammasome activation, however their suppressive ability was recovered
following in vivo treatment with IFNb. Thus, our data demonstrate that human P2X7R-mediated NLRP3 inflammasome
activation is regulated by activated CD4+CD45RO+ memory T cells, and provide new information on the mechanisms
mediating the therapeutic effects of IFNb in MS.
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Introduction
IL-1b is a potent cytokine that acts on different cell types to
induce a proinflammatory response [1], thus the production of
active IL-1b is tightly regulated. Familial autoinflammatory
syndromes, such as Muckle-Wells-Syndrome, are linked to
excessive secretion of IL-1b and have helped to elucidate the
mechanisms that regulate the secretion of active IL-1b [2]. The
secretion of active IL-1b is controlled by a sophisticated multistep
process [3,4] in which the IL1B promoter is first transactivated in
response to different stimuli such as toll-like receptor (TLR)
ligands. In a second step, multiprotein complexes, termed
inflammasomes, are assembled and catalyze the maturation of
IL-1b. Nucleotide oligomerization domain receptors (NLRs) are
central components in the majority of inflammasomes, which are
complexed with other proteins to form active inflammasomes in
response to a plethora of exogenous and endogenous ligands such
as ATP, alum or monosodium urate (MSU) crystals [5]. Once
activated, the inflammasomes catalyze the proteolytic maturation
of caspase-1, which then cleaves pro-IL-1b to IL-1b [3,6].
IL-1b is important for the differentiation and survival of Th17
cells [7,8,9,10]. The important role played by Th17 cells in the
pathogenesis of multiple sclerosis (MS) suggests that inflammasome
activation contributes to the pathogenesis of the disease. Indeed,
the generation of active IL-1b by caspase-1 controls the
development of experimental autoimmune encephalomyelitis
(EAE), an experimental model of MS [11]. Furthermore, elevated
levels of caspase-1 expression are found in MS plaques and in the
peripheral blood mononuclear cells (PBMCs) of MS patients
[12,13]. Although the control of inflammasome activation plays an
important role in the generation of active IL-1b and the
encephalitogenic immune response, the mechanisms that regulate
the activity of human inflammasomes are largely unknown.
Interferon-b (IFNb) is a first line therapy in the treatment of
relapsing-remitting multiple sclerosis (MS) [14,15,16]. Early
intervention with IFNb decreases the frequency and severity of
relapses, reduces the number of brain lesions as detected on MRI
and may reduce the progression of disability [17]. However,
despite extensive research it is still not entirely clear how IFNb
exerts its beneficial effects in MS. Treatment with IFNb in MS has
been linked to the inhibition of cell migration [18], down-
regulation of cell activation [19,20], improvement of blood brain
barrier (BBB) function [21] and regulation of pro and anti-
inflammatory cytokine balance, including IL-1b [22,23].
Here we show that aCD3-activated human CD4+CD45RO+
memory T-cells primed with IFNb inhibit pro-IL-1b production
and suppress P2X7R-mediated NLRP3 inflammasome activation
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39576in a FasL dependent manner. Activated human CD4+CD45RO+
memory T-cells alone inhibited P2X7R-mediated NLRP3 inflam-
masome activation, but concomitantly increased pro-IL-1b
production with a net effect of unchanged active IL-1b release.
Priming with IFNb however unmasked the inhibitory effect on
NLRP3 inflammasome activation by additionally reducing pro-IL-
1b production. Activated IFNb–primed CD4+CD45RO+ mem-
ory T-cells from multiple sclerosis (MS) patients were not as
effective in suppressing NLRP3 inflammasome activation as
compared to healthy controls. However memory T-cells from
MS patients treated with IFNbwere as suppressive as memory T-
cells from healthy controls. Thus, our data demonstrate that
human NLRP3 inflammasome is regulated by activated
CD4+CD45RO+ memory T cells, and provides new information
on the mechanisms mediating the therapeutic effects of IFNb in
MS.
Materials and Methods
Subjects
Peripheral blood was obtained after receipt of written informed
consent from healthy subjects and MS patients. The study was
approved by the institutional review board at Brigham and
Women’s hospital for the study of human blood (FWA 00000484).
All patients were seen at the Partners Multiple Sclerosis Center at
Brigham and Women’s Hospital. MS patients consisted of a group
of untreated relapsing-remitting MS patients that had not received
steroids in the last 3 months prior to blood drawing, nor IFNb in
the 10 months prior to blood drawing, nor immunosuppressive
therapy in the 3 years prior to blood drawing, as well as a group of
IFNb–treated patients. None of the patients were treated with
glatiramer acetate prior to blood drawing.
Reagents
The following human antibodies were used: purified CD3-
specific (Biolegend), neutralizing IL10-specific, neutralizing IFNc–
specific (BD Bioscience), neutralizing OX40L-specific, neutralizing
CD40L-specific, neutralizing polyclonal FasL-specific, mouse
IgG1b-Isotype (RnD Systems), APC-CD4-specific, PE-CD14-
specific (Biolegend), FITC-FasL-specific (Abcam), purified cas-
pase-1-specific (RnD Systems). Recombinant active interferon-b
was purchased from PBL Interferon Source. Ultrapure LPS was
purchased from Invivogen. recFASL and ATP were purchased
from SIGMA-Aldrich. P2X7R antagonists KN-62 and AZ
11645373 as well as BzATP were purchased from Tocris
Bioscience.
Cell Isolation and Stimulation of Cytokine Production
Peripheral blood mononuclear cells (PBMC) were obtained by
density gradient centrifugation of human peripheral blood over
Ficoll-Paque Plus (Amersham Pharmacia Biotech, Uppsala,
Sweden).
Monocytes were isolated by CD14+ microbeads (Miltenyi
Biotec) according to the manufacturer’s instructions.
CD4+CD45RO+ memory T-cells were further negatively en-
riched from the elution by depletion of non-T-memory cells and
CD4+CD45RA+ T-cells (Miltenyi Biotec).
Monocytes (50,000/well in all experiments except where
indicated) were plated into a 96-well cell culture plate and allowed
to adhere for 2–3 h after which medium (RPMI1640 containing
10%FCS, 10 mM Hepes, 2 mM L-glutamin, 100 U/ml Pencillin
and 100 ug/ml Streptomycin) was replaced by medium containing
different stimuli and/or CD4+CD45RO+ memory T-cells
(100,000/well in all experiments except where indicated). The
cells were co-incubated overnight and 100 ng/ml ultrapure LPS
was added the following morning for 4 h and subsequently
500 uM ATP for 45 min.
Cytokine Assays
Levels of IL-1b, pro-IL-1b, sFasL, TNFa, sCaspase–1 and IL-
10 in culture supernatants or serum were determined by ELISA
using commercial kits from Biolegend (IL-1b and TNFa), RnD
Systems (sFasL, pro-IL-1b and Caspase-1) and BD Bioscience (IL-
10) following the manufacturer’s instructions.
Intracellular Cytokine Measurement
Flow cytometric analysis was conducted as described previously
[24]. Samples were acquired on FACSCalibur or LSR II flow
cytometers (BD Beckinson). Data analysis was performed using the
FloJo software (Orlando, FL, USA).
Immunoblotting
For immunoblotting cells were lysed with RIPA buffer (20 mM
Tris–HCl pH 7.4,150 mM NaCl, 1 mM MgCl2, 1 mM CaCl2,
1% Triton X-100) supplemented with protease inhibitor cocktail
(Sigma). Lysates were centrifuged to remove particulate matters,
resolved on 4–12% Bis-Tris Nupage gels (Invitrogen) and
transferred onto PVDF membranes (Millipore). Membranes were
blocked for 1 h at room temperature in Tris-buffered saline
containing 0.05% Tween 20 (TBST) and 5% dry-milk powder and
were subsequently incubated with primary (in TBST with 5%
BSA) and appropriate secondary antibodies (in TBST with 5%
dry-milk powder). Proteins were visualized using SuperSignal West
Femto Maximum Sensitivity Substrate, as instructed by the
manufacturer (Pierce).
Size Exclusion Chromatography
Fractions were achieved by running supernatant on a Superdex
75 prep grade 206500 mm column (GE Healthcare, Little
Chalfont, UK). 500 ul of 106 concentrated supernatant was
injected onto the columns and eluted with 50 mm ammonium
acetate pH 8.5. An Amersham AKTA fast protein liquid
chromatograph (FPLC) (Amersham Biosciences, Piscataway, NJ,
USA) was used to collect 1 ml fractions, which were lyophilized
and resuspended in complete medium.
Microarray Analysis
RNA integrity was confirmed using an Agilent 2100 Bioana-
lyzer (Agilent, Palo Alto, CA) and total RNA samples where then
further processed and hybridized to Human Gene ST1.0 Arrays
(Affymetrix) according to manufacturer’s instructions. Microarray
data from biological replicates were combined and normalized
using Nexus. Student’s t-test was used to test for significant
differences between gene expression levels of different samples. A
correction for the false discovery rate (FDR) was not used in this
pair-wise comparison. Only genes that were significantly modu-
lated (p value ,0.01) and passed a fold change of FC .2.0 were
implemented in differential gene expression signatures and
considered for further analysis. All data are MIAME compliant
and raw data were submitted to the MIAME compliant database
GEO.
Quantitative RT-PCR
Total RNA was isolated using the RNeasy micro Kit (Qiagen)
and reverse transcribed with the High Capacity cDNA Tran-
scription Kit (Applied Biosystems). Quantitative RTPCR was
performed on a 7500 Fast Real-Time PCR System (Applied
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PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39576Figure 1. IFNb inhibits IL-1b release in the presence of activated human CD4+CD45RO+ memory T-cells. Monocytes were incubated
overnight in the absence or presence of unstimulated or soluble aCD3 (0.5 ug/ml) activated CD4+CD45RO+CD45RA- memory T-cells with or without
1000 IU/ml IFNb. The next day 100 ng/ml LPS was added to the co-culture for 4 h, followed by addition of 500 uM ATP for 45 min; a) IL-1b (n=8) and
b) TNFa levels (n=5) were measured in the supernatant by ELISA. There was a significant reduction of IL-1b release in the presence of activated T-
cells and IFNb; TNFa secretion was not affected; c) memory T-cells were incubated with IFNb either in the presence or absence of 2 ug/ml aCD3 and
aCD28 for 18 h, washed twice with PBS and co-incubated with monocytes for 14 h. The release of IL-1b by monocytes after stimulation with LPS and
ATP was suppressed by co-incubation with activated IFNb-primed memory T-cells (n=3) (Data are shown as means 6 SD of duplicate cultures;
*p,0.05; ***p,0.001 employing repeated measures ANOVA with post-hoc Bonferroni adjustment for multiple comparisons to avoid random
correlations); d) immunoblot of pro-IL-1b cleavage and pro-caspase-1 levels in the cell lysate of monocytes.
doi:10.1371/journal.pone.0039576.g001
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Applied Biosystems.
LDH Cytotoxicity Assay
LDH released from the cells was measured according to
manufacturer’s instructions (CytoTox 96H Non-Radioactive Cy-
totoxicity Assay, Promega). Briefly, cell supernatant was measured
for LDH reactivity by enzymatic reaction and measured with a
Tecan Infinite F200 microplate reader.
Intracellular Ca
2+ Concentration Assay
Intracellular Ca
2+ concentrations were measured using the
compound Fluo4 (Invitrogen) according to manufacturer’s in-
structions. Briefly, cells were loaded with the calcium detecting dye
for 1 h before measurement of intracellular Ca
2+ concentrations
upon stimulation with ATP with a FACSCalibur flow cytometer
(BD Beckinson).
Statistics
Data were analyzed by one-way Anova followed by Bonferroni
post-test using Prism 4.0 or paired t-test where applicable.
Differences were considered statistically significant at p,0.05.
Results
IFNb Treated Activated CD4+CD45RO+ Memory T-cells
Suppress NLRP3 Inflammasome Activation and Active IL-
1b Release by Monocytes
The NLR family, pyrin domain containing 3 (NLRP3)
inflammasome activates caspase-1, which then cleaves pro-IL-1b
to IL-1b; thus this signaling pathway is an important player in the
pathogenesis of both MS and EAE [11,12,25]. IFNb, a first-line
therapy for relapsing-remitting MS (RRMS), has been shown to
reduce IL-1b secretion by PBMCs. Based on the importance of
NLRP3 for the production of mature IL-1b [5], we studied the
effect of IFNb on the activation of the NLRP3 inflammasome in
monocytes. We used an in vitro system to study the regulation of
active IL-1b by IFNb. Human monocytes were pre-incubated
overnight with IFNb or medium, LPS was added to induce the
production of pro-IL-1b and the NLRP3 inflammasome was
activated by addition of ATP. Preincubation with IFNb prior to
the addition of LPS and ATP did not affect the release of IL-1b
(Fig 1a), suggesting that IFNb does not act directly on monocytes
to regulate the production of active IL-1b.
Murine memory T-cells inhibit the activation of the NLRP1
and NLRP3 inflammasome in a contact dependent manner
through the engagement of tumor necrosis factor receptors
(TNFR) [26]. Thus, we studied whether IFNb triggers T-cell-
dependent mechanisms that inhibit inflammasome activation in
monocytes. We first studied the effect of activated human
CD4+CD45RO+CD45RA- memory T-cells on the release of
IL-1b by human macrophages. In contrast to the findings of
Guarda et al in murine cells [26], we found that the co-incubation
of monocytes with human CD4+ memory T cells had no effect on
the release of IL-1b by human monocytes (Fig 1a). However, the
addition of exogenous IFNb to the CD4+ memory T-cell
monocyte (TM) co-culture led to a marked decrease in the release
of mature IL-1b (Fig 1a), similar effects were found when the
cleavage of pro-IL-1b was analyzed by WB (Fig 1d). In contrast,
no inhibitory effect of IFNb-primed memory T-cells was detected
on the secretion of TNFa (Fig 1b). Analogous to memory T-cells,
naı ¨ve CD4+CD45RA+CD45RO-T-cells and regulatory
CD4+CD25+ T-cells were analysed for their inhibitory effect on
secretion of IL-1b by monocytes. Naı ¨ve T-cells had a comparable,
though somewhat reduced inhibitory effect on monocytes, whereas
regulatory T-cells did not have an effect on the secretion of IL-1b
(Fig.S1).
To rule out the possibility of a direct effect of IFNb on
monocytes, we preincubated CD4+ memory T-cells overnight
with plate-bound aCD3 and aCD28 antibodies in the presence of
IFNb, removed IFNb by extensive washing and co-incubated the
pre-treated T-cells with monocytes for 14 hours. IL-1b release by
monocytes after LPS and ATP stimulation was again decreased
after co-incubation with IFNb-primed activated CD4+ memory
T-cells (Fig 1c).
NLRP3 inflammasome can be activated by various other
signals such as Alum or MSU crystals that involve unspecific
membrane disruption rather than P2X7R activation. To
investigate whether NLRP3 inflammasome inactivation was
confined to ATP mediated ligation of P2X7R we tested other
P2X7R-independent NLRP3 inflammasome activators. Surpris-
ingly, neither stimulation with Alum (Fig 2a) nor with
monosodium urate (MSU) crystals (Fig 2b) was inhibited by
IFNb–primed memory T-cells. Also NLRP1 inflammasome
activation by MDP was not inhibited by incubation with
IFNb-primed memory T-cells (Fig 2c), suggesting that the
inhibitory effect of IFNb-primed activated CD4+CD45RO+
memory T-cells on pro-IL-1b cleavage is specific to ATP-
mediated P2X7R-activation. Thus, IFNb-primed memory T-
cells inhibit ATP-triggered NLRP3 inflammasome activation
and the release of active IL-1b by monocytes.
Soluble Caspase-1 Release is Decreased in Monocytes
Cultured with Activated CD4+CD45RO+ Memory T-cells
Upon activation, the NLRP3 inflammasome activates caspase-
1, which then cleaves pro-IL-1b to mature IL-1b. Therefore,
inflammasome activation is reflected by increased cellular levels
of active caspase-1, which is rapidly secreted from the cells [5].
Our data suggested the post-transcriptional regulation of IL-1b
release by IFNb-primed memory T-cells, thus we investigated
the effect that co-culture of IFNb-treated CD4+ memory T-cells
with monocytes might have on inflammasome activity and the
production of soluble caspase-1 (sCaspase-1). We found that
sCaspase-1 levels were decreased in the presence of activated T-
cells, with or without the addition of IFNb (Fig 3a). This
observation seemed contradictory, as this decrease in the levels
of sCaspase-1 in the co-culture with aCD3 activated T-cells was
not mirrored by a decrease in IL-1b secretion. However, when
we measured intracellular levels of pro-IL-1b in the different
culture conditions we found a marked upregulation in the levels
of pro-IL-1b in monocytes co-cultured with activated T-cells
(Fig 3b). Thus, the ratio of pro-IL-1b to sCaspase-1 was
significantly increased in the co-culture of activated CD4+
memory T-cells and monocytes suggesting that the release of
mature IL-1b is controlled not only by the availability of active
caspase-1, but also by the concentration of pro-IL-1b in the
cells (Fig 3c).
The purinergic receptor P2X7R triggers the assembly of the
NLRP3 inflammasome in response to ATP [27,28]. We found that
the decrease in sCaspase-1 levels in the supernatants was
associated with a decrease in P2X7R mRNA expression (Fig 3d).
Upon ATP binding, P2X7R mediates a slow sustained influx of
extracellular calcium that follows an initial fast efflux of
intracellular calcium stores mediated by the purinergic receptor
P2Y [29]. Thus, P2X7R function can be investigated employing a
functional calcium flux assay [30]. Monocytes co-incubated with
activated CD4+CD45+ memory T-cells in the presence of IFNb
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39576Figure 2. Inhibition of NLRP3 inflammasome activation by IFNb-primed human CD4+CD45RO+ memory T-cells is ATP-specific. IL-1b
release after incubation with a) Alum (400 ug/ml) (n=3), b) MSU crystals (300 ug/ml) (n=3) and c) MDP (10 ug/ml) (n=3) was not inhibited by co-
incubation of monocytes with IFNb-primed CD4+CD45RO+ memory T-cells (Data are shown as means 6 SD of duplicate cultures; ***p,0.01
employing repeated measures ANOVA with post-hoc Bonferroni adjustment for multiple comparisons to avoid random correlations).
doi:10.1371/journal.pone.0039576.g002
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39576Figure 3. Activated CD4+ CD45RO+ memory T-cells decrease secretion of soluble caspase-1 and P2X7R mRNA expression in
monocytes leading to a reduced response upon ATP binding. a) sCaspase-1 levels in the supernatant of monocytes was measured by ELISA
(n=8). A significant decrease of soluble Caspase-1 in the supernatant of cells co-cultured with activated memory T-cells was observed both in the
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39576showed a significant reduction in calcium influx (Fig 3e) suggesting
that IFNb-primed activated CD4+CD45RO+ memory T-cells
control the response to ATP. Addition of P2X7R specific
inhibitors led to a comparable inhibition of Ca
2+-influx (Fig.S2)
further validating the applicability of the assay to measure
inihibition of P2X7R-induced Ca
2+-influx. Stimulation of mono-
cytes with the P2X7R specific agonist BzATP led to a comparable
Ca
2+-influx that was also inhibited by addition of memory T-cells
in the presence of aCD3 and IFNb (Fig.S3). In summary,
activated CD4+CD45RO+ memory T-cells suppress ATP-trig-
gered NLRP3 inflammasome activation in monocytes by the
inhibition of P2X7R-mediated signaling.
presence and absence of IFNb; b) intracellular levels of pro-IL-1b measured with an ELISA specific for the immature precursor of IL-1b showed a
significant increase in pro-IL-1b levels in the presence of human activated CD4+CD45RO+ memory T-cells (n=3), cell lysates from adherent
monocytes were obtained after removal of non-adherent T-cells after addition of LPS and prior to incubation with ATP c) the ratio of intracellular pro-
IL-1b to released soluble Caspase-1 is significantly increased in the presence of human activated CD4+CD45RO+ memory T-cells (n=3). d) P2X7R
mRNA expression in monocytes cultured overnight with activated CD4+CD45RO+ memory T-cells is decreased with and without addition of
exogenous IFNb (n=3), mRNA was isolated from adherent monocytes after removal of non-adherent T-cells after addition of LPS and prior to
incubation with ATP (Data are shown as means 6 SD of duplicate cultures; *p,0.05; **p,0.01 employing repeated measures ANOVA with post-hoc
Bonferroni adjustment for multiple comparisons to avoid random correlations); e) Ca
2+-influx measurement in monocytes cultured with activated
human CD4+CD45RO+ memory T-cells in the presence of IFNb demonstrates the absence of slow sustained Ca
2+-influx mediated by ATP binding to
the purinergic P2X7-receptor (representative of 3 independent experiments); f) Annexin V staining of monocytes coincubated with T-cells and
stimulated with LPS was measured by flow cytometry (representative flow cytometry histogram of n=5).
doi:10.1371/journal.pone.0039576.g003
Figure 4. IL10 does not mediate the observed suppression of active IL-1b release. a) memory CD4+CD45RO+ T-cells cultured overnight in
the presence of monocytes with or without aCD3 and/or IFNb were restimulated with PMA/Ionomycin in the presence of Brefeldin A for 4 h and
stained for IL-10 and IFNc (representative of 3 independent experiments); b) upregulation of IL10 mRNA expression in resorted memory T-cells was
confirmed by qPCR (n=3; n.d.=not detected); c) inhibition of IL-10 (10 ug/ml) and/or IFNc (10 ug/ml) by specific blocking antibodies did not affect
the suppressive effect on IL-1b release by activated T-cells in the presence of IFNb (n=4) (% suppression is calculated by subtracting from 1 the ratio
of IL-1b release from activated T-cells in the presence of IFNb and non-activated T-cells in the absence of IFNb and multiplying by 100; **p,0.01
employing repeated measures ANOVA with post-hoc Bonferroni adjustment for multiple comparisons to avoid random correlations).
doi:10.1371/journal.pone.0039576.g004
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IL-10
Treatment with IFNb leads to an increase in the levels of the
anti-inflammatory cytokine IL-10 in the circulation [31]. Thus, we
analyzed the role of IL-10 in the inhibition of IL-1b release by
IFNb. Intracellular cytokine staining showed an increase in IL-10
and IFNc positive T-cells in response to in vitro IFNb treatment
(Fig 4a). Similarly, we also found an upregulation in IL10 mRNA
expression in resorted activated T-cells that were cultured in the
presence of IFNb and monocytes (Fig 4b).
We thus investigated the role of IL-10 in the control of IL-1b
release by IFNb-treated memory T cells. The addition of
exogenous recombinant IL-10 suppressed IL-1b production, and
this suppression was abrogated by addition of IL-10 blocking
antibody (Fig.S4). Strikingly, although IL-10 suppressed IL-1b
release, validated blocking antibodies to IL-10 had no effect on the
suppression of IL-1b release by IFNb (Fig 4c). Furthermore
analysis of mRNA expression revealed inhibition of IL1B
transcription by monocytes co-incubated with T-cells in the
presence of aCD3 and IFNb which was inhibited by co-incubation
with an IL-10-blocking antibody (Fig.S5). Thus, although IL-10
inhibits IL1B expression at the transcriptional level [32], IFNb also
triggers IL-10 independent post-transcriptional regulatory mech-
anisms that suppress the release of active IL-1b by monocytes.
The Suppression of Inflammasome Activation is
Mediated by a Soluble Factor
We next analyzed whether the inhibitory effect of CD4+
memory T-cells is contact-dependent and mediated by TNFR
family members as reported in murine cells [26]. Blocking
antibodies specific for the TNFR family members CD40L and
OX40L did not affect the suppression of IL-1b release by IFNb-
treated memory T-cells (Fig 5a). Furthermore T-cells can
upregulate the surface molecule CD39 an ecto-enzyme that
hydrolyzes ATP to ADP. We tested whether upregulation of
CD39 by aCD3 activation and IFNb stimulation could contribute
to the inhibitory effect on IL-1b secretion by monocytes. mRNA of
FACS-resorted CD4+CD45RO+ memory T-cells was isolated and
relative mRNA expression of CD39 was determined. However
CD39 mRNA expression was decreased in T-cells after stimulation
with aCD3 and IFNb in the T-cell monocyte co-culture (Fig 5b),
thus CD39 does not seem to be involved in the suppression of IL-
1b release.
In further experiments we incubated monocytes with superna-
tant conditioned by a co-culture of monocytes and memory T-cells
and observed a comparable inhibitory effect (Fig 5c), suggesting
that the suppression of IL-1b release in monocytes is mediated by
a soluble factor.
Next we analyzed the kinetics of the production of the factor
responsible for the inhibition of IL-1b release. Fresh monocytes
were incubated overnight with supernatants taken at different
time-points from co-cultures of memory T-cells and monocytes.
We found a direct correlation between increasing time of co-
culture and inhibition of active IL-1b secretion (Fig 5d). To
estimate the molecular weight of the soluble factor that mediates
the suppression of inflammasome activation by CD4+CD45RO+
memory T-cells we used molecular weight cut-off filters. Super-
natants were fractioned with molecular weight cut-off filters of
100, 50 and 30 kDa and the flow-throughs were collected and
cultured with fresh monocytes. The factor responsible for the
inhibition of IL-1b release was still present when flow-throughs of
100 kDa, and 50 kDa cut-off filters were tested on monocytes, but
not when the flow-through of 30 kDa cut-off filters was used
(Fig 5e). Thus, we estimated the molecular weight of the IL-1b
release inhibitory factor to be in the range of 30–50 kDa. Size
exclusion chromatography further confirmed and narrowed down
the molecular weight range to 23–38 kDa (Fig 5f – of note the
observed difference of inhibition in high molecular weight
fractions was thought secondary to high molecular weight of
nutrients such as BSA). In conclusion, memory T-cells co-cultured
with monocytes in the presence of IFNband aCD3 release a
soluble factor of 23–38 kDa that inhibits inflammasome activation
and the secretion of active IL-1b.
FasL Contributes to the Inhibition of IL-1b Release by
Monocytes
To identify the soluble factor responsible for the decreased
release of IL-1b we performed a microarray analysis. Live CD3+
CD4+ T-cells from the monocyte T-cell co-culture were re-
isolated by FACS sorting and gene expression was analyzed with
Gene ST1.0 microarrays (Affymetrix). We then used three criteria
to select candidate molecules mediating inflammasome inhibition
in monocytes: 1) upregulation by co-culture of memory T-cells
with monocytes and IFNb, 2) molecular weight between 23–
38 kDa and 3) existence of a soluble form. We identified FasL,
LGALS9, APOL1 and SPP1 as matching candidates (Fig 6a). We
confirmed the upregulation of these candidates in T-cell-monocyte
co-cultures by qPCR (Fig 6b). To investigate the biological
relevance of these candidates we used blocking antibodies specific
for the identified candidates or purified APOL1. We found that
only FasL was involved in the inhibitory effect of IFNb-treated
memory T-cells on IL-1b release, as addition of FasL blocking
antibodies diminished the suppression of IL-1b release (Fig 6c).
However, as the inhibition was not completely reversed, another
yet unidentified soluble factor seems to be involved. Expression of
FasL on the cell surface was demonstrated by flow cytometry and
an increase in soluble FasL (sFasL) in the supernatant of the co-
culture was shown by ELISA (Fig 6d and e). Addition of recFasL
led to an inhibition of IL-1b release itself, however not statistically
significant, further crosslinking of recFasL by addition of tag-
specific antibody led to a significant decrease of IL-1b release
(Fig 6f). Of note, a potential increase in apoptosis was ruled out by
Figure 5. Suppression of IL-1b release is cell contact independent and mediated by a soluble factor of 23–38 kDa MW. a) Blocking
OX40L and CD40L pathways by the use of inhibitory antibodies did not affect the suppressive effect of activated T-cells on monocytes in the
presence of IFNb (n=3; % suppression calculated as described in Fig 4); b) CD39 mRNA expression by memory T-cells resorted after co-culture with
monocytes was measured by qPCR (n=3) (Data are shown as means 6 SD of duplicate cultures; *p,0.01 employing repeated measures ANOVA with
post-hoc Bonferroni adjustment for multiple comparisons to avoid random correlations); c) transfer of supernatant conditioned by a co-culture of
monocytes and activated memory CD4+ T-cells in the presence of IFNb onto fresh monocytes reproduced the suppressive effect on IL-1b release
(n=4); d) Kinetics of the inhibitory factor release and determination of molecular weight; supernatants of monocytes co-cultured with activated
human memory T-cells in the presence of IFNb were removed at the indicated time-points and fresh monocytes were cultured in the conditioned
supernatants for 16 h before stimulation with LPS and activation with ATP (representative of 2 independent experiments); e) supernatants were
filtered through molecular cut-off filters or f) SEC fractionated and molecular weight fractions in a 1:1 ratio with fresh medium were used for the
culture of fresh monocytes. IL-1b secretion was measured and inhibition of release was calculated according to Fig 4 (representative of 2
independent experiments).
doi:10.1371/journal.pone.0039576.g005
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in the presence of monocytes with and without IFNb for 16 h and resorted by gating on CD3+CD4+7AAD- cells, upregulated candidates that fit the
criteria of presence of a soluble form and molecular weight of 23–38 kDa are displayed; b) qPCR confirmation of upregulation of SSP1, LGALS9,
APOL1 and FasL mRNA expression through incubation with IFNb (n=3); c) analysis of biological relevance of upregulated molecules by the use of
blocking antibodies (10 ug/ml), only blockage of FasL significantly decreased the inhibitory effect on IL-1b release (n=3) (% suppression calculated as
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IFNb triggers the secretion of FasL by human CD4+ CD45RO+
memory T-cells, which then contributes to the inhibition of the
release of mature IL-1b by monocytes.
Influence of IFNb Treatment on Inflammasome
Activation in MS Patients
IL-1b in combination with IL-21, TGFb and IL-23, promotes
the differentiation and expansion of Th17 cells [7,8,9,10,33],
which are thought to play an important role in the pathogenesis of
MS [34]. Increased frequencies of Th17 cells have been found in
MS patients [35]. Thus, we studied whether the suppressive
activity of CD4+CD45RO+ memory T cells on IL-1b secretion
was impaired in MS patients. CD4+CD45RO+ memory T-cells of
MS patients were isolated and co-cultured with monocytes from
healthy controls. We found that the suppressive activity of
CD4+CD45RO+ memory T-cells on IL-1b secretion by mono-
cytes was significantly reduced in untreated MS patients compared
to healthy controls (p,0.05) (Fig 7a). Treatment with IFNb
reversed this reduced suppressive effect as CD4+ memory T-cells
of IFNb-treated MS patients showed a comparable suppressive
activity to healthy controls (Fig 6a). Having found that IFNb–
induced sFasL contributes to the down-regulation of IL-1b release
in vitro, we investigated whether FasL induction is associated with
reduction of IL-1b secretion in response to the treatment with
IFNb. IFNb–treated MS patients showed a significant increase in
sFasL serum levels as compared to healthy controls and untreated
MS patients (Fig 7b). Taken together these data suggest that
treatment with IFNb leads to increased suppressive ability of
CD4+CD45RO+ memory T-cells on IL-1b secretion by mono-
cytes partly through an increase in sFasL serum levels.
Discussion
The secretion of IL-1b is tightly controlled by inflammasomes,
multi-protein complexes composed of NLR and adaptor proteins
that aggregate upon exposure to specific activators. Owing to their
central role in the secretion of active IL-1b, inflammasomes play
an important role in the control of the immune response to tumors
[36] and infections [37], and also in autoimmune diseases such as
MS [38]. Thus, it is important to characterize the regulatory
mechanisms that control inflammasome activation. Although it
has recently been shown that CD4+ memory T-cells control the
activation of murine NLRP3 and NLRP1 inflammasomes [26],
the mechanisms controlling human inflammasome activation are
largely unknown. Here we show that activated human
CD4+CD45RO+ memory T-cells primed with IFNb suppress
pro-IL-1b production and the P2X7R-mediated activation of
NLRP3 inflammasome in a partly FasL-dependent manner,
through a mechanism different from that involved in the control
of murine inflammasomes.
described in Fig 4); d) soluble FasL levels were measured with a FasL specific ELISA in the supernatants of co-cultured activated CD4+CD45RO+
memory T-cells (n=3); e) surface expression of FasL is measured after overnight co-culture by staining with FasL specific antibody and acquisition of
cells by flow cytometry (representative of 3 independent experiments); f) IL-1b release is inhibited by recFasL in the presence of a crosslinking
antibody (n=3) (Data are shown as means 6 SD of duplicate cultures; *p,0.05, **p,0.01, ***p,0.001 employing repeated measures ANOVA with
post-hoc Bonferroni adjustment for multiple comparisons to avoid random correlations).
doi:10.1371/journal.pone.0039576.g006
Figure 7. CD4+CD45RO+ memory T-cells of untreated MS patients are defective in the IFNb-induced suppressive ability on active
IL-1b release by monocytes. This suppressive ability is rescued by in vivo treatment with IFNb and is associated with increased serum levels of
sFasL in IFNb-treated MS patients; a) monocytes of HC (healthy controls) were cultured overnight with allogenic activated memory T-cells from HC
(n=13), untreated (n=11) or IFNb-treated MS patients (n=10) and the suppressive effect of exogenous IFNb on IL-1b release was measured as
described in Fig 4; activated memory T-cells of MS patients showed a significantly decreased suppressive effect when compared to healthy controls,
which was reversed by in vivo treatment with IFNb; b) FasL levels in the serum of healthy controls (HC) (n=24), untreated MS patients (MS) (n=19)
and IFNb-treated MS patients (MS-IFNb) (n=16) were measured by ELISA; IFNb treated MS patients showed an increased level of sFasL when
compared to untreated MS patients and healthy controls; (*p,0.05; **p,0.01 employing repeated measures ANOVA with post-hoc Bonferroni
adjustment for multiple comparisons to avoid random correlations).
doi:10.1371/journal.pone.0039576.g007
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the activation of mouse inflammasomes by mechanisms dependent
on ligands of the TNFR family, such as CD40L and RANKL [26].
Our data suggest that human NLRP3 inflammasome is regulated
differently. We found that activated human CD4+CD45RO+
memory T cells did not suppress active IL-1b release unless they
had been previously pre-activated with IFNb. Activated human
CD4+CD45RO+ memory T-cells increase the production of pro-
IL-1b in monocytes, but at the same time downregulate P2X7R
mRNA expression and consequently, the influx of extracellular
calcium following ATP stimulation. Thus these two limiting steps
of active IL-1b secretion are counter regulated and eventually lead
to a net unchanged secretion of active IL-1b. Priming of activated
human CD4+CD45RO+ memory T-cells with IFNb renders the
T–cells able to also inhibit the production of pro-IL-1b in
monocytes. Therefore IFNb-priming unmasks the ability of
activated human CD4+CD45RO+ memory T-cells to inhibit
ATP-mediated NLRP3 inflammasome activation through a partly
FasL-dependent mechanism that is apoptosis-independent [39,40].
Thus, activated human CD4+CD45RO+ memory T-cells regulate
the NLRP3 inflammasome activation in monoyctes by controlling
the response of monocytes to ATP.
The activation of NLRP3 inflammasome by P2X7R-indepen-
dent triggers such as Alum and MSU crystals was not affected by
co-incubation with IFNb-primed activated CD4+CD45RO+
memory T-cells, suggesting that the inhibition of NLRP3
inflammasome activation is restricted to ATP-mediated P2X7R
signaling. Previous reports on inhibition of inflammasome
activation in murine cells have demonstrated stimulus nonspecific
inactivation [26], suggesting inhibition upstream of inflammasome
assembly but downstream of stimulus-specific signaling. Thus, this
is the first report of a stimulus specific inhibition of inflammasome
activation, demonstrating that inflammasome activation can be
inhibited in a stimulus-specific manner, without affecting poten-
tially important alternative triggering mechanisms needed to fight
off pathogens. ATP is quickly released from cells upon encoun-
tering stress such as tissue trauma or infection [41] and P2X7R-
mediated neuroinflammation has been previously attributed an
important role in the development of EAE [42]. Currently specific
CNS-penetrant P2X7R-antagonists are being developed to be
used as anti-inflammatory medication in neuroinflammatory
diseases such as MS [43] emphasizing the importance of the
pro-inflammatory function of ATP-triggered P2X7R activation.
It has recently been reported that type I interferon acts directly
on mouse macrophages and human monocytes to inhibit
inflammasome activation [32]. Our data do not support a direct
effect of IFNb on human monocytes during the suppression of
inflammasome activation. We believe that the discrepancies
between our study and that of Guarda et al reflect differences in
the regulatory mechanisms that control murine and human
inflammasome activation.
IFNb is a first line therapy for RRMS [14,15,16]. We found that
IFNb-primed CD4+CD45RO+ memory T-cells from untreated
MS patients have an impaired ability to suppress ATP-mediated
NLRP3 inflammasome activation and IL-1b release in monocytes.
However, this impaired suppressive activity was not found when we
analyzed samples from IFNb-treated patients. Thus, supplementa-
tion of IFNb in vivo might prime CD4+ CD45RO+ memory T-cells
to become more responsive to stimulation with IFNb in vitro.
Alternatively, a specific subpopulation of CD4+CD45RO+ mem-
ory T-cells responsible for the suppression of inflammasome
activation in monocytes might be decreased or dysfunctional in
untreated MS patients, but recovered following treatment with
IFNb. The innate immune system plays an important role in
multiple sclerosis and infections have been shown to trigger MS
exacerbations, thus the regulation of TLR and ATP-induced
NLRP3 inflammasome activation by IFNb might contribute to the
beneficial effects of IFNb treatment in MS [44].
The regulation of pro-IL-1b production and NLRP3 inflamma-
some activation by IFNb-primed activated CD4+CD45RO+
memory T cells might also play a role in limiting immunopathology
during the immune response to viruses. The immune response to
viral infections is usually characterized by the production of high
levels of IFNb, which triggers a cascade of anti-viral mechanisms
[15]. Our data demonstrate that in addition to its direct anti-viral
effects, IFNb also triggers a negative feedback loop that ultimately
arrests inflammasome activation and IL-1b production. In combi-
nation with other anti-inflammatory effects of IFNb such as the
inhibition of the differentiation of Th17 cells [45] and the
promotion of the differentiation of Tr1 cells [46], the suppression
of pro-IL-1b production and inflammasome activation by IFNb-
primed activated CD4+CD45RO+ memory T cells is likely to limit
the immune response triggered by infections. Moreover, consider-
ingthelinkageexistingbetweeninfectionsandMS[47],itispossible
that deficits in the ability of CD4+CD45RO+ memory T cells to
control the immune response triggered by pathogens might play a
role in the development of MS.
In conclusion, we describe a new mechanism by which
CD4+CD45RO+ memory T cells control human innate immu-
nity. Activated CD4+CD45RO+ memory T-cells primed by
IFNb, which itself is produced by cells of the innate immune
system upon activation, down-regulate the production of pro-IL-
1b and the response of monocytes to ATP and consequently,
P2X7R-mediated NLRP3 inflammasome activation in a partly
FasL-dependent manner. This negative feedback loop mediated
by human IFNb and activated CD4+CD45RO+ memory T–cells
is likely to limit inflammation and immunopathology during the
course of the immune response to viruses, and might contribute to
the therapeutic effects of IFNb in MS.
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Figure S1 Effect of naı ¨ve and regulatory T-cells on IL-1b
release by monocytes. a) Naı ¨ve CD4
+CD45RO
-CD45RA
+
(FACS sorted) T-cells inhibit IL-1b release by monocytes in the
presence of aCD3 and IFNb; b) CD4
+CD25
+ regulatory T-cells
do not inhibit IL-1b release by monocytes in the presence of aCD3
and IFNb50.000 cells/well CD4
+CD25
+ (FACS-sorted) regulatory
T-cells co-incubated with 50.000 cells/well monocytes, a T-cell/
monocyte ratio in memory T-cells that is sufficient for inhibition of
IL-1b release (not shown)).
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Figure S2 ATP induced Ca
2+-influx is inhibited by
specific P2X7R-antagonists. a) Ca
2+-influx induced by ATP
in the absence of inhibitor (red), in the presence of 10 uM KN-62
(blue), in the presence of 100 uM KN-62 (green); b) Ca
2+-influx
induced by ATP in the absence of inhibitor (red), in the presence
of 10 uM AZ 11645373 (blue), in the presence of 100 uM AZ
11645373 (green).
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Figure S3 BzATP induces Ca
2+-influx comparable to
ATP and, which is inhibited by co-incubation with
activated T-cells in the presence of IFNb. a) ATP induced
Ca
2+-influx (red) is comparable to BzATP induced Ca
2+-influx
(blue); b) BzATP-induced Ca
2+-influx in the presence of T-cells
with (red) or without aCD3 and IFNb (blue).
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abrogated by a specific IL10-blocking antibody (10 ug/
ml) (**p,0.01 employing repeated measures ANOVA
with post-hoc Bonferroni adjustment for multiple com-
parisons to avoid random correlations).
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Figure S5 mRNA expression of IL1B is inhibited by co-
incubation of monocytes with T-cells in the presence of
aCD3 and IFNb, this inhibition is reversed by addition of
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repeated measures ANOVA with post-hoc Bonferroni
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